A Precise Approach to Treating Prostate Cancer: Focal Therapy Program Expands at Mount Sinai
Mount Sinai is expanding its use of an image-guided technology that focuses on removing only cancerous tissue in the prostate, sparing the rest of the gland. The technique presents a contrast to traditional approaches, where removing the entire prostate leaves patients safe from cancer, but facing profound sexual and urinary side effects.
Focal therapy is a technique of treating only the cancerous areas of the prostate, not affecting the rest of the prostate. The focal therapy program at Mount Sinai will be the first to use fusion biopsy technology to deliver treatment more precisely. Fusion-guided biopsy, an imaging technique which combines MRI and ultrasound imaging to better visualize the prostate during procedures, has been in use at Mount Sinai since 2013 for use in obtaining biopsy samples.
The newly expanded program will be led by Art R. Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology and Associate Professor of Urology and Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Rastinehad, who joined Mount Sinai from the North Shore-LIJ Health System in January, is a recognized leader in the design of the imaging and the screening techniques at the foundation of focal therapy. In collaboration with the National Cancer Institute and Philips Health care, for instance, Dr. Rastinehad helped to develop the first fusion biopsy device.
“We are extremely pleased to welcome Dr. Rastinehad to Mount Sinai,” said Ash Tewari, MD, the Kyung Hyun Kim, MD Chair of Urology at the Mount Sinai Health System and Professor of Urology at the Icahn School of Medicine at Mount Sinai. “I look forward to working with Art to further develop our focal therapy initiative.”
Dr. Rastinehad is the first dual fellowship trained urological oncologist to practice interventional urology. In his new position, he will work with other industry leaders at the Icahn School of Medicine at Mount Sinai to advance a multidisciplinary approach to treating prostate cancer.
Since joining the Mount Sinai Health System, Dr. Rastinehad led the first international course on MRI/US fusion guided biopsies, sponsored by the American Urological Association and hosted at the Icahn School of Medicine at Mount Sinai in December of last year. Dr. Rastinehad will lead future courses at Mount Sinai including one held in March. For more information, visit https://www.auanet.org/education/courses/MRFUS151.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.